

Personalized Schedules for Surveillance of Low Risk Prostate Cancer Patients

Anirudh Tomer^{1,*}, Daan Nieboer², Monique J. Roobol³,
Ewout W. Steyerberg^{2,4}, and Dimitris Rizopoulos¹

¹Department of Biostatistics, Erasmus University Medical Center, the Netherlands

²Department of Public Health, Erasmus University Medical Center, the Netherlands

³Department of Urology, Erasmus University Medical Center, the Netherlands

⁴Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, the Netherlands

**email*: a.tomer@erasmusmc.nl

SUMMARY: Low risk prostate cancer patients enrolled in active surveillance (AS) programs commonly undergo biopsies on a frequent basis for examination of cancer progression. AS programs employ a fixed schedule of biopsies for all patients. Such fixed and frequent schedules, may schedule unnecessary biopsies. Since biopsies are burdensome, patients do not always comply with the schedule, which increases the risk of delayed detection of cancer progression. Motivated by the world's largest AS program, Prostate Cancer Research International Active Surveillance (PRIAS), we present personalized schedules for biopsies to counter these problems. Using joint models for time to event and longitudinal data, our methods combine information from historical prostate-specific antigen (PSA) levels and repeat biopsy results of a patient, to schedule the next biopsy. We also present methods to compare personalized schedules with existing biopsy schedules.

KEY WORDS: Active surveillance; Biopsy; Joint models; Personalized medicine; Prostate cancer

1. Introduction

In this decade, prostate cancer (PCa) is the second most frequently diagnosed cancer (14% of all cancers) in males worldwide (Torre et al., 2015). The increase in diagnosis of low grade PCa has been attributed to increase in life expectancy and increase in number of screening programs (Potosky et al., 1995). An issue of screening programs that has also been established in other types of cancers (e.g., breast cancer) is over-diagnosis. To avoid overtreatment, patients diagnosed with low grade PCa are commonly advised to join active surveillance (AS) programs. In order to delay serious treatments such as surgery, chemotherapy, or radiotherapy, in AS PCa progression is routinely examined via serum prostate specific antigen (PSA) levels, digital rectal examination, medical imaging, and biopsy etc.

Biopsies are the most painful, prone to medical complications (Loeb et al., 2013) and yet also the most reliable PCa progression examination technique used in AS. When a patient's biopsy Gleason grading becomes larger than 6 (Gleason reclassification or GR), he is advised to switch from AS to active treatment (Bokhorst et al., 2015). Hence the timing of biopsies has significant medical implications. The world's largest AS program, Prostate Cancer Research International Active Surveillance (PRIAS) conducts biopsies at year one, year four, year seven and year ten of follow-up, and every five years thereafter. However it switches to a more frequent, annual biopsy schedule for faster progressing patients. These are patients with PSA doubling time (PSA-DT) of less than 10 years. The latter is measured as the inverse of the slope of the regression line through the base two logarithm of PSA values. However, many AS programs use annual schedule for all patients (Tosoian et al., 2011; Welty et al., 2015). Consequently, for slowly progressing PCa patients many unnecessary biopsies are scheduled. Furthermore, patients may not always comply with such schedules (Bokhorst et al., 2015), which can lead to delayed detection of PCa and reduce the effectiveness of AS.

This paper is motivated by the need to reduce the medical burden of repeat biopsies

while simultaneously avoiding late detection of PCa progression. To this end, we intend to develop personalized schedules for biopsies using historical PSA measurements and biopsy results of patients. Personalized schedules for screening have received much interest in the literature, especially in the medical decision making context. For example, Markov decision process (MDP) models have been used to create personalized screening schedules for diabetic retinopathy (Bebu and Lachin, 2017), breast cancer (Ayer, Alagoz, and Stout, 2012), cervical cancer (Akhavan-Tabatabaei, Sánchez, and Yeung, 2017) and colorectal cancer (Erenay, Alagoz, and Said, 2014). Another type of model called joint model (JM) for time to event and longitudinal data (Tsiatis and Davidian, 2004; Rizopoulos, 2012) has also been used to create personalized schedules for the measurement of longitudinal biomarkers (Rizopoulos et al., 2016). In the context of PCa, Zhang et al. (2012) have used partially observable MDP models to personalize the decision of (not) deferring a biopsy to the next checkup time during the screening process. This decision is based on the baseline characteristics as well as a discretized PSA level of the patient at the current check up time.

In comparison to the work referenced above, the schedules we propose in this paper account for the latent between-patient heterogeneity. We achieve this using JMs, which are inherently patient-specific because they utilize random effects. Secondly, JMs allow a continuous time scale and utilize the entire history of PSA levels. Lastly, instead of making a binary decision of (not) deferring a biopsy to the next pre-scheduled check up time, we schedule biopsies at a per patient optimal future time. To this end, using JMs we first obtain a full specification of the joint distribution of PSA levels and time of GR. We then use it to define a patient-specific posterior predictive distribution of the time of GR, given the observed PSA measurements and repeat biopsies up to the current check up time. Using the general framework of Bayesian decision theory, we propose a set of loss functions which are minimized to find the optimal time of conducting a biopsy. These loss functions yield us two categories of personalized

schedules, those based on expected time of GR and those based on the risk of GR. In addition we analyze an approach where the two types of schedules are combined. We also present methods to evaluate and compare the various schedules for biopsies.

The rest of the paper is organized as follows. Section 2 briefly covers the joint modeling framework. Section 3 details the personalized scheduling approaches we have proposed in this paper. In Section 4 we discuss methods for evaluation and selection of a schedule. In Section 5 we demonstrate the personalized schedules by employing them for the patients from the PRIAS program. Lastly, in Section 6, we present the results from a simulation study we conducted to compare personalized schedules with PRIAS and annual schedule.

2. Joint Model for Time to Event and Longitudinal Outcomes

We start with a short introduction of the JM framework we will use in our following developments. Let T_i^* denote the true GR time for the i -th patient and let S be the schedule of his biopsies. Let the vector of the time of biopsies be denoted by $T_i^S = \{T_{i0}^S, T_{i1}^S, \dots, T_{iN_i^S}^S; T_{ij}^S < T_{ik}^S, \forall j < k\}$, where N_i^S are the total number of biopsies conducted. Because biopsy schedules are periodical, T_i^* cannot be observed directly and it is only known to fall in an interval $l_i < T_i^* \leq r_i$, where $l_i = T_{iN_i^S-1}^S, r_i = T_{iN_i^S}^S$ if GR is observed, and $l_i = T_{iN_i^S}^S, r_i = \infty$ if GR is not observed yet. Further let \mathbf{y}_i denote the $n_i \times 1$ vector of PSA levels for the i -th patient. For a sample of n patients the observed data is denoted by $\mathcal{D}_n = \{l_i, r_i, \mathbf{y}_i; i = 1, \dots, n\}$.

The longitudinal outcome of interest, namely PSA level, is continuous in nature and thus to model it the JM utilizes a linear mixed effects model (LMM) of the form:

$$\begin{aligned} y_i(t) &= m_i(t) + \varepsilon_i(t) \\ &= \mathbf{x}_i^T(t)\boldsymbol{\beta} + \mathbf{z}_i^T(t)\mathbf{b}_i + \varepsilon_i(t), \end{aligned}$$

where $\mathbf{x}_i(t)$ and $\mathbf{z}_i(t)$ denote the row vectors of the design matrix for fixed and random effects, respectively. The fixed and random effects are denoted by $\boldsymbol{\beta}$ and \mathbf{b}_i , respectively. The random effects are assumed to be normally distributed with mean zero and $q \times q$ covariance

matrix \mathbf{D} . The true and unobserved, error free PSA level at time t is denoted by $m_i(t)$. The error $\varepsilon_i(t)$ is assumed to be t-distributed with three degrees of freedom and scale σ (see Web Appendix C.1), and is independent of the random effects \mathbf{b}_i .

To model the effect of PSA on hazard of GR, JMs utilize a relative risk sub-model. The hazard of GR for patient i at any time point t , denoted by $h_i(t)$, depends on a function of subject specific linear predictor $m_i(t)$ and/or the random effects:

$$\begin{aligned} h_i(t \mid \mathcal{M}_i(t), \mathbf{w}_i) &= \lim_{\Delta t \rightarrow 0} \frac{\Pr\{t \leq T_i^* < t + \Delta t \mid T_i^* \geq t, \mathcal{M}_i(t), \mathbf{w}_i\}}{\Delta t} \\ &= h_0(t) \exp [\boldsymbol{\gamma}^T \mathbf{w}_i + f\{\mathcal{M}_i(t), \mathbf{b}_i, \boldsymbol{\alpha}\}], \quad t > 0, \end{aligned}$$

where $\mathcal{M}_i(t) = \{m_i(v), 0 \leq v \leq t\}$ denotes the history of the underlying PSA levels up to time t . The vector of baseline covariates is denoted by \mathbf{w}_i , and $\boldsymbol{\gamma}$ are the corresponding parameters. The function $f(\cdot)$ parametrized by vector $\boldsymbol{\alpha}$ specifies the functional form of PSA levels (Brown, 2009; Rizopoulos, 2012; Taylor et al., 2013; Rizopoulos et al., 2014) that is used in the linear predictor of the relative risk model. Some functional forms relevant to the problem at hand are the following:

$$\begin{cases} f\{\mathcal{M}_i(t), \mathbf{b}_i, \boldsymbol{\alpha}\} = \alpha m_i(t), \\ f\{\mathcal{M}_i(t), \mathbf{b}_i, \boldsymbol{\alpha}\} = \alpha_1 m_i(t) + \alpha_2 m'_i(t), \quad \text{with } m'_i(t) = \frac{dm_i(t)}{dt}. \end{cases}$$

These formulations of $f(\cdot)$ postulate that the hazard of GR at time t may be associated with the underlying level $m_i(t)$ of the PSA at t , or with both the level and velocity $m'_i(t)$ of the PSA at t . Lastly, $h_0(t)$ is the baseline hazard at time t , and is modeled flexibly using P-splines. The detailed specification of the baseline hazard, and parameter estimation using the Bayesian approach are presented in Web Appendix A of the supplementary material.

3. Personalized Schedules for Repeat Biopsies

We intend to use the JM fitted to \mathcal{D}_n , to create personalized schedules of biopsies. To this end, let us assume that a schedule is to be created for a new patient j , who is not present in

\mathcal{D}_n . Let t be the time of his latest biopsy, and $\mathcal{Y}_j(s)$ denote his historical PSA measurements up to time s . The goal is to find the optimal time $u > \max(t, s)$ of the next biopsy.

3.1 Posterior Predictive Distribution for Time to GR

The information from $\mathcal{Y}_j(s)$ and repeat biopsies is manifested by the posterior predictive distribution $g(T_j^*)$, given by (baseline covariates \mathbf{w}_i are not shown for brevity hereafter):

$$\begin{aligned} g(T_j^*) &= p\{T_j^* \mid T_j^* > t, \mathcal{Y}_j(s), \mathcal{D}_n\} \\ &= \int p\{T_j^* \mid T_j^* > t, \mathcal{Y}_j(s), \boldsymbol{\theta}\} p(\boldsymbol{\theta} \mid \mathcal{D}_n) d\boldsymbol{\theta} \\ &= \int \int p(T_j^* \mid T_j^* > t, \mathbf{b}_j, \boldsymbol{\theta}) p\{\mathbf{b}_j \mid T_j^* > t, \mathcal{Y}_j(s), \boldsymbol{\theta}\} p(\boldsymbol{\theta} \mid \mathcal{D}_n) d\mathbf{b}_j d\boldsymbol{\theta}. \end{aligned}$$

The distribution $g(T_j^*)$ depends on $\mathcal{Y}_j(s)$ and \mathcal{D}_n via the posterior distribution of random effects \mathbf{b}_j and posterior distribution of the vector of all parameters $\boldsymbol{\theta}$, respectively.

3.2 Loss Functions

To find the time u of the next biopsy, we use principles from statistical decision theory in a Bayesian setting (Berger, 1985; Robert, 2007). More specifically, we propose to choose u by minimizing the posterior expected loss $E_g\{L(T_j^*, u)\}$, where the expectation is taken with respect to $g(T_j^*)$. The former is given by:

$$E_g\{L(T_j^*, u)\} = \int_t^\infty L(T_j^*, u) p\{T_j^* \mid T_j^* > t, \mathcal{Y}_j(s), \mathcal{D}_n\} dT_j^*.$$

Various loss functions $L(T_j^*, u)$ have been proposed in literature (Robert, 2007). The ones we utilize, and the corresponding motivations are presented next.

Given the burden of biopsies, ideally only one biopsy performed at the exact time of GR is sufficient. Hence, neither a time which overshoots the true GR time T_j^* , nor a time which undershoots it, is preferred. In this regard, the squared loss function $L(T_j^*, u) = (T_j^* - u)^2$ and the absolute loss function $L(T_j^*, u) = |T_j^* - u|$ have the properties that the posterior expected loss is symmetric on both sides of T_j^* . Secondly, both loss functions have well known

solutions available. The posterior expected loss for the squared loss function is given by:

$$\begin{aligned} E_g\{L(T_j^*, u)\} &= E_g\{(T_j^* - u)^2\} \\ &= E_g\{(T_j^*)^2\} + u^2 - 2uE_g(T_j^*). \end{aligned} \quad (1)$$

The posterior expected loss in (1) attains its minimum at $u = E_g(T_j^*)$, that is, the expected time of GR. The posterior expected loss for the absolute loss function is given by:

$$\begin{aligned} E_g\{L(T_j^*, u)\} &= E_g(|T_j^* - u|) \\ &= \int_u^\infty (T_j^* - u)g(T_j^*)dT_j^* + \int_t^u (u - T_j^*)g(T_j^*)dT_j^*. \end{aligned} \quad (2)$$

The posterior expected loss in (2) attains its minimum at $u = \text{median}_g(T_j^*)$, that is, the median time of GR. It can also be expressed as $\pi_j^{-1}(0.5 | t, s)$, where $\pi_j^{-1}(\cdot)$ is the inverse of dynamic survival probability $\pi_j(u | t, s)$ of patient j (Rizopoulos, 2011). It is given by:

$$\pi_j(u | t, s) = \Pr\{T_j^* \geq u | T_j^* > t, \mathcal{Y}_j(s), D_n\}, \quad u \geq t.$$

Even though $E_g(T_j^*)$ or $\text{median}_g(T_j^*)$ may be obvious choices from a statistical perspective, from the viewpoint of doctors or patients, it could be more intuitive to make the decision for the next biopsy by placing a cutoff $1 - \kappa$, where $0 \leq \kappa \leq 1$, on the dynamic incidence/risk of GR. This approach would be successful if κ can sufficiently well differentiate between patients who will obtain GR in a given period of time versus others. This approach is also useful when patients are apprehensive about delaying biopsies beyond a certain risk cutoff. Thus, a biopsy can be scheduled at a time point u such that the dynamic risk of GR is higher than a certain threshold $1 - \kappa$, beyond u . To this end, the posterior expected loss for the following multilinear loss function can be minimized to find the optimal u :

$$L_{k_1, k_2}(T_j^*, u) = \begin{cases} k_2(T_j^* - u), k_2 > 0 & \text{if } T_j^* > u, \\ k_1(u - T_j^*), k_1 > 0 & \text{otherwise,} \end{cases}$$

where k_1, k_2 are constants parameterizing the loss function. The posterior expected loss $E_g\{L_{k_1, k_2}(T_j^*, u)\}$ obtains its minimum at $u = \pi_j^{-1}\{k_1/(k_1 + k_2) | t, s\}$ (Robert, 2007). The choice of the two constants k_1 and k_2 is equivalent to the choice of $\kappa = k_1/(k_1 + k_2)$.

In practice, for some patients we may not have sufficient information to accurately estimate their PSA profile. The resulting high variance of $g(T_j^*)$ could lead to a mean (or median) time of GR which overshoots the true T_j^* by a big margin. In such cases, the approach based on dynamic risk of GR with smaller risk thresholds is more risk averse and thus could be more robust to large overshooting margins. This consideration leads us to a hybrid approach, namely, to select u using dynamic risk of GR based approach when the spread of $g(T_j^*)$ is large, while using $E_g(T_j^*)$ or $\text{median}_g(T_j^*)$ when the spread of $g(T_j^*)$ is small. What constitutes a large spread will be application-specific. In PRIAS, within the first 10 years, the maximum possible delay in detection of GR is three years. Thus we propose that if the difference between the 0.025 quantile of $g(T_j^*)$, and $E_g(T_j^*)$ or $\text{median}_g(T_j^*)$ is more than three years then proposals based on dynamic risk of GR be used instead.

3.3 Estimation

Since there is no closed form solution available for $E_g(T_j^*)$, for its estimation we utilize the following relationship between $E_g(T_j^*)$ and $\pi_j(u | t, s)$:

$$E_g(T_j^*) = t + \int_t^\infty \pi_j(u | t, s) du. \quad (3)$$

However, as mentioned earlier, selection of the optimal biopsy time based on $E_g(T_j^*)$ alone will not be practically useful when the $\text{var}_g(T_j^*)$ is large, which is given by:

$$\text{var}_g(T_j^*) = 2 \int_t^\infty (u - t) \pi_j(u | t, s) du - \left\{ \int_t^\infty \pi_j(u | t, s) du \right\}^2. \quad (4)$$

Since there is no closed form solution available for the integrals in (3) and (4), we approximate them using Gauss-Kronrod quadrature (see Web Appendix B). The variance depends both on last biopsy time t and PSA history $\mathcal{Y}_j(s)$, as demonstrated in Section 5.2.

For schedules based on dynamic risk of GR, the choice of threshold κ has important consequences because it dictates the timing of biopsies. Often it may depend on the amount of risk that is acceptable to the patient (if maximum acceptable risk is 5%, $\kappa = 0.95$). When κ cannot be chosen on the basis of the input of the patients, we propose to automate its

choice. More specifically, given the time t of latest biopsy we propose to choose a κ for which a binary classification accuracy measure (López-Ratón et al., 2014), discriminating between cases (patients who experience GR) and controls, is maximized. In JMs, a patient j is predicted to be a case in the time window Δt if $\pi_j(t + \Delta t \mid t, s) \leq \kappa$, or a control if $\pi_j(t + \Delta t \mid t, s) > \kappa$ (Rizopoulos, 2016; Rizopoulos, Molenberghs, and Lesaffre, 2017). We choose Δt to be one year. This is because, in AS programs at any point in time, it is of interest to identify and provide extra attention to patients who may obtain GR in the next one year. As for the choice of the binary classification accuracy measure, we chose F_1 score since it is in line with our goal to focus on potential cases in time window Δt . F_1 score combines both sensitivity and positive predictive value (PPV) and is defined as:

$$F_1(t, \Delta t, s) = 2 \frac{\text{TPR}(t, \Delta t, s) \text{PPV}(t, \Delta t, s)}{\text{TPR}(t, \Delta t, s) + \text{PPV}(t, \Delta t, s)},$$

$$\text{TPR}(t, \Delta t, s) = \Pr\{\pi_j(t + \Delta t \mid t, s) \leq \kappa \mid t < T_j^* \leq t + \Delta t\},$$

$$\text{PPV}(t, \Delta t, s) = \Pr\{t < T_j^* \leq t + \Delta t \mid \pi_j(t + \Delta t \mid t, s) \leq \kappa\},$$

where $\text{TPR}(\cdot)$ and $\text{PPV}(\cdot)$ denote time dependent true positive rate (sensitivity) and positive predictive value (precision), respectively. The estimation for both is similar to the estimation of $\text{AUC}(t, \Delta t, s)$ given by Rizopoulos et al. (2017). Since a high F_1 score is desired, the corresponding value of κ is $\arg \max_{\kappa} F_1(t, \Delta t, s)$. We compute the latter using a grid search approach. That is, first F_1 score is computed using the available dataset over a fine grid of κ values between 0 and 1, and then κ corresponding to the highest F_1 score is chosen. Furthermore, in this paper we use κ chosen only on the basis of F_1 score.

3.4 Algorithm

When a biopsy gets scheduled at a time $u < T_j^*$, then GR is not detected at u and at least one more biopsy is required at an optimal time $u^{new} > \max(u, s)$. This process is repeated until GR is detected. To aid in medical decision making, we elucidate this process via an

algorithm in Figure 1. Since AS programs strongly advise that two biopsies have a gap of at least one year, when $u - t < 1$, the algorithm postpones u to $t + 1$, because it is the time nearest to u , at which the one year gap condition is satisfied.

[Figure 1 about here.]

4. Evaluation of Schedules

In order to compare various schedules of biopsies, we require measures of their efficacy. We propose to use two measures, namely the number of biopsies (burden) $N_j^S \geq 1$ a schedule S conducts for the j -th patient to detect GR, and the offset $O_j^S \geq 0$ by which it overshoots T_j^* . The offset O_j^S is defined as $O_j^S = T_{jN_j^S}^S - T_j^*$, where $T_{jN_j^S}^S \geq T_j^*$ is the time at which GR is detected. Our interest lies in the joint distribution $p(N_j^S, O_j^S)$ of the number of biopsies and the offset. The least burdensome scenario is when $N_j^S = 1$ and $O_j^S = 0$. Hence, realistically we should select a schedule with a low mean number of biopsies $E(N_j^S)$ as well a low mean offset $E(O_j^S)$. It is also desired that a schedule has low variance for both the number of biopsies $\text{var}(N_j^S)$, and offset $\text{var}(O_j^S)$, so that the schedule works similarly for most patients.

4.1 Choosing a Schedule

Given the multiple schedules of biopsies, it is of clinical interest to choose a suitable schedule. Using principles from compound optimal designs (Läuter, 1976) we propose to choose a schedule S which minimizes a loss function of the following form:

$$L(S) = \sum_{r=1}^R \eta_r \mathcal{R}_r(N_j^S), \quad (5)$$

where $\mathcal{R}_r(\cdot)$ is a function of either N_j^S or O_j^S (for brevity, only N_j^S is used in the equation above). Some examples of $\mathcal{R}_r(\cdot)$ are mean, median, variance and quantile function. Constants η_1, \dots, η_R , where $0 \leq \eta_r \leq 1$ and $\sum_{r=1}^R \eta_r = 1$, are weights to differentially weigh-in the contribution of each of the R criteria. An example loss function is:

$$L(S) = \eta_1 E(N_j^S) + \eta_2 E(O_j^S). \quad (6)$$

The choice of η_1 and η_2 is not easy, because the burden of a biopsy cannot be compared to a unit increase in offset easily. To obviate this problem we utilize the equivalence between compound and constrained optimal designs (Cook and Wong, 1994). More specifically, it can be shown that for any η_1 and η_2 there exists a constant $C > 0$ for which minimization of the loss function in (6) is equivalent to minimization of the loss function subject to the constraint that $E(N_j^S) < C$. That is, a schedule which conducts at most C biopsies on average and detects GR earliest should be chosen. The choice of C could be based on the number of biopsies a patient is willing to undergo. In the more generic case in (5), a schedule can be chosen by minimizing $\mathcal{R}_R(\cdot)$ under the constraint $\mathcal{R}_r(\cdot) < C_r; r = 1, \dots, R - 1$.

5. Demonstration of Personalized Schedules

To demonstrate the personalized schedules, we apply them to the patients enrolled in PRIAS study. To this end, we divide the PRIAS dataset into a training part (5264 patients) and a demonstration part (three patients). We fit a JM to the training dataset and then use it to create schedules for the demonstration patients. We fit the JM using the R package **JMbayes** (Rizopoulos, 2016), which uses the Bayesian approach for parameter estimation.

5.1 Fitting the Joint Model to the PRIAS Dataset

For each of the PRIAS patients, we know their age at the time of inclusion in AS, PSA history and the time interval in which GR is detected. For the longitudinal analysis of PSA we use \log_2 PSA measurements instead of the raw data (Nieboer et al., 2015). The longitudinal sub-model of the JM we fit is given by:

$$\begin{aligned} \log_2 \text{PSA}(t) = & \beta_0 + \beta_1(\text{Age} - 70) + \beta_2(\text{Age} - 70)^2 + \sum_{k=1}^4 \beta_{k+2} B_k(t, \mathcal{K}) \\ & + b_{i0} + b_{i1} B_7(t, 0.1) + b_{i2} B_8(t, 0.1) + \varepsilon_i(t), \end{aligned} \quad (7)$$

where $B_k(t, \mathcal{K})$ denotes the k -th basis function of a B-spline with three internal knots at $\mathcal{K} = \{0.1, 0.5, 4\}$ years, and boundary knots at zero and seven (0.99 quantile of the observed

follow-up times) years. The spline for the random effects consists of one internal knot at 0.1 years and boundary knots at zero and seven years. For the relative risk sub-model the hazard function we fit is given by:

$$h_i(t) = h_0(t) \exp \{ \gamma_1(\text{Age} - 70) + \gamma_2(\text{Age} - 70)^2 + \alpha_1 m_i(t) + \alpha_2 m'_i(t) \}, \quad (8)$$

where α_1 and α_2 are measures of strength of the association between hazard of GR and \log_2 PSA value $m_i(t)$ and \log_2 PSA velocity $m'_i(t)$, respectively.

From the fitted JM we found that \log_2 PSA velocity and the age at the time of inclusion in AS were significantly associated with the hazard of GR. For any patient, an increase in \log_2 PSA velocity from -0.10 to 0.14 (first and third quartiles of the fitted velocities, respectively) corresponds to a 2.02 fold increase in the hazard of GR. In terms of the predictive performance, we found that the area under the receiver operating characteristic curves (Rizopoulos et al., 2017) was 0.61, 0.65 and 0.59 at year one, year two, and year three of follow-up, respectively. Parameter estimates are presented in detail in Web Appendix C.

In PRIAS, the interval $l_i < T_i^* \leq r_i$ in which GR is detected depends on the PSA-DT of the patient. However, because the parameters are estimated using a full likelihood approach (Tsiatis and Davidian, 2004), the JM gives valid estimates for all of the parameters, under the condition that the model is correctly specified (see Web Appendix A.2 and C.3). To this end, we performed several sensitivity analysis in our model (e.g., changing the position of the knots, etc.) to investigate the fit of the model and also the robustness of the results. In all of our attempts, the same conclusions were reached, namely that the \log_2 PSA velocity is more strongly associated with the hazard of GR compared to the \log_2 PSA levels.

5.2 Personalized Schedules for the First Demonstration Patient

We now demonstrate the functioning of the personalized schedules for the first demonstration patient (see Web Appendix D for the other two demonstration patients). The fitted and observed \log_2 PSA profile, time of latest biopsy and proposed biopsy times u for him are

shown in the top panel of Figure 2. We can see that with a consistently decreasing PSA and negative repeat biopsy between year three and year 4.5, the proposed time of biopsy based on dynamic risk of GR has increased from 3.05 years ($\kappa = 0.94$) to 13.73 years ($\kappa = 0.96$) in this period. The proposed time of biopsy based on expected time of GR has also increased from 14.22 years to 16.07 years. We can also see in the bottom panel of Figure 2 that after each negative repeat biopsy, $SD[T_j^*] = \sqrt{\text{var}_g(T_j^*)}$ decreases sharply. Thus, if the expected time of GR based approach is used, then the offset O_j^S will be smaller on average for biopsies scheduled after the second repeat biopsy than those scheduled after the first repeat biopsy.

[Figure 2 about here.]

6. Simulation Study

In Section 5.2 we demonstrated that the personalized schedules, schedule future biopsies according to the historical data of each patient. However we could not perform a full scale comparison between personalized and PRIAS schedules, because the true time of GR was not known for the PRIAS patients. To this end, we conducted a simulation study comparing personalized schedules with PRIAS and annual schedule, whose details are presented next.

6.1 Simulation Setup

The population of AS patients in this simulation study is assumed to have the same entrance criteria as that of PRIAS. The PSA and hazard of GR for these patients follow a JM of the form postulated in Section 5.1, with parameters equal to the posterior mean of parameters estimated from the JM fitted to the PRIAS dataset (see Web Appendix C). Furthermore, we also intend to test the efficacy of different schedules for a population which has patients with both faster as well as slowly progressing PCa. The rate of progression is not only manifested via PSA profiles, but also via baseline hazard. We assume that there are three equal sized subgroups G_1 , G_2 and G_3 of patients in the population, each with a baseline hazard from

a Weibull distribution, with the following shape and scale parameters (k, λ) : $(1.5, 4)$, $(3, 5)$ and $(4.5, 6)$ for G_1, G_2 and G_3 , respectively. The effect of these parameters is that the mean GR time is lowest in G_1 (fast PCa progression) and highest in G_3 (slow PCa progression).

From this population we have sampled 500 datasets with 1000 patients each. We generate a true GR time for each of the patients, and then sample a set of PSA measurements at the same time points as given in PRIAS protocol (see Web Appendix C). We then split the dataset into a training (750 patients) and a test (250 patients) part, and generate a random and non-informative censoring time for the training patients. We next fit a JM of the specification given in (7) and (8) to each of the 500 training datasets, and obtain MCMC samples from the 500 sets of posterior distribution of the parameters. Using these fitted JMs, we obtain the posterior predictive distribution of time of GR for each of the 500×250 test patients. This distribution is further used to create personalized biopsy schedules for the test patients. For every test patient we conduct hypothetical biopsies using the following six types of schedules (abbreviated names in parenthesis): personalized schedules based on expected time of GR (Exp. GR time) and median time of GR (Med. GR time), personalized schedules based on dynamic risk of GR (Dyn. risk GR), a hybrid approach between median time of GR and dynamic risk of GR (Hybrid), PRIAS schedule and annual schedule. The biopsies are conducted iteratively in accordance with the algorithm in Figure 1.

To compare the aforementioned schedules we require estimates of the various measures of efficacy described in Section 4. To this end, for schedule S , we compute pooled estimates of mean offset $E(O_j^S)$ and variance of offset $\text{var}(O_j^S)$, as below (estimates for N_j^S are similar):

$$\begin{aligned} \widehat{E(O_j^S)} &= \frac{\sum_{k=1}^{500} n_k \widehat{E(O_k^S)}}{\sum_{k=1}^{500} n_k}, \\ \widehat{\text{var}(O_j^S)} &= \frac{\sum_{k=1}^{500} (n_k - 1) \widehat{\text{var}(O_k^S)}}{\sum_{k=1}^{500} (n_k - 1)}, \end{aligned}$$

where n_k denotes the number of test patients, $\widehat{E(O_k^S)} = \sum_{l=1}^{n_k} O_{kl}^S / n_k$ is the estimated mean

and $\widehat{\text{var}}(O_k^S) = \sum_{l=1}^{n_k} \{O_{kl}^S - \widehat{E}(O_k^S)\}^2 / (n_k - 1)$ is the estimated variance of the offset for the k -th simulation. The offset for the l -th test patient of the k -th dataset is denoted by O_{kl}^S .

6.2 Results

The pooled estimates of the aforementioned measures are summarized in Table 1. In addition, estimated values of $E(O_j^S)$ are plotted against $E(N_j^S)$ in Figure 3. The figure shows that across the schedules there is an inverse relationship between number $E(O_j^S)$ and $E(N_j^S)$. For example, the annual schedule conducts on average 5.2 biopsies to detect GR, which is the highest among all schedules. However it has the least average offset of 6 months as well. On the other hand the schedule based on expected time of GR conducts only 1.9 biopsies on average to detect GR, the least among all schedules, but it also has the highest average offset of 15 months (similar for median time of GR). Since the annual schedule attempts to contain the offset within an year it has the least $\text{SD}(O_j^S) = \sqrt{\text{var}(O_j^S)}$. However to achieve this, it conducts a wide range of number of biopsies from patient to patient, i.e., highest $\text{SD}(N_j^S) = \sqrt{\text{var}(N_j^S)}$. In this regard, schedules based on expected and median time of GR perform the opposite of annual schedule.

[Figure 3 about here.]

[Table 1 about here.]

The PRIAS schedule conducts only 0.3 biopsies less than the annual schedule, but with a higher $\text{SD}(O_j^S)$, early detection is not always guaranteed. In comparison, the dynamic risk of GR based schedule performs slightly better than the PRIAS schedule in all four criteria. The hybrid approach combines the benefits of methods with low $E(N_j^S)$ and $\text{SD}(N_j^S)$, and methods with low $E(O_j^S)$ and $\text{SD}(O_j^S)$. It conducts 1.5 biopsies less than the annual schedule on average and with a $E(O_j^S)$ of 9.7 months it detects GR within an year since its occurrence. Moreover, it has both $\text{SD}(N_j^S)$ and $\text{SD}(O_j^S)$ comparable to PRIAS.

The performance of each schedule differs for the three subgroups G_1 , G_2 and G_3 . The annual schedule remains the most consistent across subgroups in terms of the offset, but it conducts 2 extra biopsies for subgroup G_3 (slowly progressing PCa) than G_1 (faster progressing PCa). The performance of schedule based on expected time of GR is the most consistent in terms of number of biopsies but it detects GR an year later on average in subgroup G_1 than G_3 . For the dynamic risk of GR based schedule and the hybrid schedule the dynamics are similar to that of the annual schedule. Unlike the latter two schedules, the PRIAS schedule not only conducts more biopsies in G_3 than G_1 but also detects GR later in G_3 than G_1 .

[Figure 4 about here.]

[Figure 5 about here.]

The choice of a suitable schedule using (5) depends on the chosen measure for evaluation of schedules. In this regard, the schedules we compared either have high $SD(O_j^S)$ and low $SD(N_j^S)$, or vice versa (Table 1). Thus, applying a cutoff on $E(O_j^S)$ when $SD(O_j^S)$ is high may not be as fruitful (same for N_j^S) as applying a cutoff on $SD(O_j^S)$ or quantile(s) of O_j^S . For example, the schedule based on dynamic risk of GR is suitable if on average the least number of biopsies are to be conducted to detect GR, while simultaneously making sure that at least 90% of the patients have an average offset less than one year.

7. Discussion

In this paper we presented personalized schedules based on joint models for time to event and longitudinal data, for surveillance of PCa patients. These schedules are dynamic in nature, and at any given follow-up time, utilize a patient's historical PSA measurements and repeat biopsies conducted up to that time. We proposed two types of personalized schedules, namely those based on expected and median time of GR of a patient, and those based on dynamic risk of GR. We also proposed a combination (hybrid approach) of these two approaches, which

is useful in scenarios where variance of time of GR for a patient is high. We then proposed criteria for evaluation of various schedules and a method to select a suitable schedule.

We demonstrated the dynamic and personalized nature of our schedules using the PRIAS dataset. We observed that a recent biopsy impacts the schedules more than recent PSA measurements, which correlates with biopsies being more reliable. Since true GR time is not known for PRIAS patients, we conducted a simulation study to compare personalized schedules with PRIAS and annual schedules. The latter two schedules are already in practice. Hence it can be argued that the maximum possible offsets due to these schedules (one and three years, respectively) are acceptable to doctors. Thus, less frequent schedules with offset under one year may reduce the burden of biopsies while simultaneously being practical. For example, for slowly progressing patients in our simulation study, we observed that the schedule based on expected time of GR conducts on average two biopsies and has an average offset of 10 months. In comparison, annual schedule conducts six biopsies on average and gives an offset smaller by only four months, making the personalized schedule a suitable alternative. For high risk patients however, early detection (annual or PRIAS schedule) may be necessary, given the rapidness of progression. When it is not known in advance if a patient will have a fast or slow progression of PCa, the hybrid approach may be used. It conducts one biopsy less than the annual schedule in faster progressing PCa patients and has an average offset of 10.25 months. For slowly progressing PCa patients it conducts two biopsies less than the annual schedule and has an average offset of 8.55 months.

More personalized schedules can be added to the current set, using loss functions which asymmetrically penalize overshooting/undershooting the target GR time. For dynamic risk of GR based schedules, more simulations are required to compare data driven κ values (e.g., F_1 score), with κ chosen using decision analytic approaches such as the net benefit measure (Vickers and Elkin, 2006), and with various fixed κ values used by doctors in practice. In

general the Gleason scores are susceptible to inter-observer variation (Carlson et al., 1998). Schedules which account for error in measurement of time of GR will be interesting to investigate further (Coley et al., 2017). Lastly, there is potential for including diagnostic information from magnetic resonance imaging (MRI) or DRE. When such information is not continuous in nature, our proposed methodology can be easily extended by utilizing the framework of generalized linear mixed models.

ACKNOWLEDGEMENTS

The first and last authors would like to acknowledge support by the Netherlands Organization for Scientific Research’s VIDI grant nr. 016.146.301, and Erasmus MC funding. The authors also thank the Erasmus MC Cancer Computational Biology Center for giving access to their IT-infrastructure and software that was used for the computations and data analysis in this study. Lastly, we thank Frank-Jan H. Drost from the Department of Urology, Erasmus University Medical Center, for helping us in accessing the PRIAS data set.

SUPPLEMENTARY MATERIALS

Web Appendix A, B, and C, D referenced in Section 2, Section 3.3 and Section 5, respectively, are available in the document `supplementary_material.pdf`.

REFERENCES

- Akhavan-Tabatabaei, R., Sánchez, D. M., and Yeung, T. G. (2017). A Markov decision process model for cervical cancer screening policies in Colombia. *Medical Decision Making* **37**, 196–211.
- Ayer, T., Alagoz, O., and Stout, N. K. (2012). A POMDP approach to personalize mammography screening decisions. *Operations Research* **60**, 1019–1034.
- Bebu, I. and Lachin, J. M. (2017). Optimal screening schedules for disease progression with application to diabetic retinopathy. *Biostatistics* doi:10.1093/biostatistics/kxx009.

- Berger, J. O. (1985). *Statistical Decision Theory and Bayesian Analysis*. Springer Science & Business Media.
- Bokhorst, L. P., Alberts, A. R., Rannikko, A., Valdagni, R., Pickles, T., Kakehi, Y., Bangma, C. H., Roobol, M. J., and PRIAS study group (2015). Compliance rates with the Prostate Cancer Research International Active Surveillance (PRIAS) protocol and disease reclassification in noncompliers. *European Urology* **68**, 814–821.
- Brown, E. R. (2009). Assessing the association between trends in a biomarker and risk of event with an application in pediatric HIV/AIDS. *The Annals of Applied Statistics* **3**, 1163–1182.
- Carlson, G. D., Calvanese, C. B., Kahane, H., and Epstein, J. I. (1998). Accuracy of biopsy Gleason scores from a large uropathology laboratory: use of a diagnostic protocol to minimize observer variability. *Urology* **51**, 525–529.
- Coley, R. Y., Zeger, S. L., Mamawala, M., Pienta, K. J., and Carter, H. B. (2017). Prediction of the pathologic Gleason score to inform a personalized management program for prostate cancer. *European Urology* **72**, 135–141.
- Cook, R. D. and Wong, W. K. (1994). On the equivalence of constrained and compound optimal designs. *Journal of the American Statistical Association* **89**, 687–692.
- Erenay, F. S., Alagoz, O., and Said, A. (2014). Optimizing colonoscopy screening for colorectal cancer prevention and surveillance. *Manufacturing & Service Operations Management* **16**, 381–400.
- Läuter, E. (1976). Optimal multipurpose designs for regression models. *Mathematische Operationsforschung und Statistik* **7**, 51–68.
- Loeb, S., Vellekoop, A., Ahmed, H. U., Catto, J., Emberton, M., Nam, R., Rosario, D. J., Scattoni, V., and Lotan, Y. (2013). Systematic review of complications of prostate biopsy. *European Urology* **64**, 876–892.

- López-Ratón, M., Rodríguez-Álvarez, M. X., Cadarso-Suárez, C., and Gude-Sampedro, F. (2014). OptimalCutpoints: an R package for selecting optimal cutpoints in diagnostic tests. *Journal of Statistical Software* **61**, 1–36.
- Nieboer, D., Vergouwe, Y., Roobol, M. J., Ankerst, D. P., Kattan, M. W., Vickers, A. J., Steyerberg, E. W., and the Prostate Biopsy Collaborative Group (2015). Nonlinear modeling was applied thoughtfully for risk prediction: the Prostate Biopsy Collaborative Group. *Journal of clinical epidemiology* **68**, 426–434.
- Potosky, A. L., Miller, B. A., Albertsen, P. C., and Kramer, B. S. (1995). The role of increasing detection in the rising incidence of prostate cancer. *JAMA* **273**, 548–552.
- Rizopoulos, D. (2011). Dynamic predictions and prospective accuracy in joint models for longitudinal and time-to-event data. *Biometrics* **67**, 819–829.
- Rizopoulos, D. (2012). *Joint Models for Longitudinal and Time-to-Event Data: With Applications in R*. CRC Press.
- Rizopoulos, D. (2016). The R package JMbays for fitting joint models for longitudinal and time-to-event data using MCMC. *Journal of Statistical Software* **72**, 1–46.
- Rizopoulos, D., Hatfield, L. A., Carlin, B. P., and Takkenberg, J. J. (2014). Combining dynamic predictions from joint models for longitudinal and time-to-event data using Bayesian model averaging. *Journal of the American Statistical Association* **109**, 1385–1397.
- Rizopoulos, D., Molenberghs, G., and Lesaffre, E. M. (2017). Dynamic predictions with time-dependent covariates in survival analysis using joint modeling and landmarking. *Biometrical Journal* doi:10.1002/bimj.201600238.
- Rizopoulos, D., Taylor, J. M. G., Van Rosmalen, J., Steyerberg, E. W., and Takkenberg, J. J. M. (2016). Personalized screening intervals for biomarkers using joint models for longitudinal and survival data. *Biostatistics* **17**, 149–164.

- Robert, C. (2007). *The Bayesian choice: from decision-theoretic foundations to computational implementation*. Springer Science & Business Media.
- Taylor, J. M., Park, Y., Ankerst, D. P., Proust-Lima, C., Williams, S., Kestin, L., Bae, K., Pickles, T., and Sandler, H. (2013). Real-time individual predictions of prostate cancer recurrence using joint models. *Biometrics* **69**, 206–213.
- Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., and Jemal, A. (2015). Global cancer statistics, 2012. *CA: A Cancer Journal for Clinicians* **65**, 87–108.
- Tosoian, J. J., Trock, B. J., Landis, P., Feng, Z., Epstein, J. I., Partin, A. W., Walsh, P. C., and Carter, H. B. (2011). Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. *Journal of Clinical Oncology* **29**, 2185–2190.
- Tsiatis, A. A. and Davidian, M. (2004). Joint modeling of longitudinal and time-to-event data: an overview. *Statistica Sinica* **14**, 809–834.
- Vickers, A. J. and Elkin, E. B. (2006). Decision curve analysis: a novel method for evaluating prediction models. *Medical Decision Making* **26**, 565–574.
- Welty, C. J., Cowan, J. E., Nguyen, H., Shinohara, K., Perez, N., Greene, K. L., Chan, J. M., Meng, M. V., Simko, J. P., Cooperberg, M. R., and Carroll, P. R. (2015). Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. *The Journal of Urology* **193**, 807–811.
- Zhang, J., Denton, B. T., Balasubramanian, H., Shah, N. D., and Inman, B. A. (2012). Optimization of prostate biopsy referral decisions. *Manufacturing & Service Operations Management* **14**, 529–547.

Received October 0000. Revised February 0000. Accepted March 0000.




Figure 1. Algorithm for creating a personalized schedule for patient j . The time of the latest biopsy is denoted by t . The time of the latest available PSA measurement is denoted by s . The proposed personalized time of biopsy is denoted by u . The time at which a repeat biopsy was proposed on the last visit to the hospital is denoted by u^{pv} . The time of the next visit for the measurement of PSA is denoted by s^{nv} .




Figure 2. Top panel: Fitted versus observed \log_2 PSA profile, history of repeat biopsies and corresponding personalized schedules for the first demonstration patient. Bottom Panel: History of repeat biopsies and $\text{SD}_g(T_j^*) = \sqrt{\text{var}_g(T_j^*)}$ over time for the first demonstration patient.




Figure 3. Estimated mean number of biopsies and mean offset (months) for various schedules, obtained from the simulation study with 500 simulated datasets.




Figure 4. Boxplot showing variation in number of biopsies conducted by various schedules, obtained from the simulation study with 500 simulated datasets.




Figure 5. Boxplot showing variation in biopsy offset (months) for various schedules, obtained from the simulation study with 500 simulated datasets.

Table 1

Estimated mean and standard deviation of the number of biopsies and offset (months) for various schedules, obtained from the simulation study with 500 simulated datasets.

a) All hypothetical subgroups				
Schedule	$E(N_j^S)$	$E(O_j^S)$	$SD(N_j^S)$	$SD(O_j^S)$
Annual	5.24	6.01	2.53	3.46
PRIAS	4.90	7.71	2.36	6.31
Dyn. risk GR	4.69	6.66	2.19	4.38
Hybrid	3.75	9.70	1.71	7.25
Med. GR time	2.06	13.88	1.41	11.80
Exp. GR time	1.92	15.08	1.19	12.11
b) Hypothetical subgroup G_1				
Schedule	$E(N_j^S)$	$E(O_j^S)$	$SD(N_j^S)$	$SD(O_j^S)$
Annual	4.32	6.02	3.13	3.44
PRIAS	4.07	7.44	2.88	6.11
Dyn. risk GR	3.85	6.75	2.69	4.44
Hybrid	3.25	10.25	2.16	8.07
Med. GR time	1.84	20.66	1.76	14.62
Exp. GR time	1.72	21.65	1.47	14.75
c) Hypothetical subgroup G_2				
Schedule	$E(N_j^S)$	$E(O_j^S)$	$SD(N_j^S)$	$SD(O_j^S)$
Annual	5.18	5.98	2.13	3.47
PRIAS	4.85	7.70	2.00	6.29
Dyn. risk GR	4.63	6.66	1.82	4.37
Hybrid	3.68	10.32	1.37	7.45
Med. GR time	1.89	12.33	1.16	9.44
Exp. GR time	1.77	13.54	0.98	9.83
d) Hypothetical subgroup G_3				
Schedule	$E(N_j^S)$	$E(O_j^S)$	$SD(N_j^S)$	$SD(O_j^S)$
Annual	6.20	6.02	1.76	3.46
PRIAS	5.76	7.98	1.71	6.51
Dyn. risk GR	5.58	6.58	1.56	4.33
Hybrid	4.32	8.55	1.26	5.91
Med. GR time	2.45	8.70	1.15	6.32
Exp. GR time	2.27	10.09	0.99	7.47